Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?

Blood Reviews

Volumn 30, Issue 2, 2016, Pages 89-100

  Iqbal, Javeed ^a   Wilcox, Ryan ^b   Naushad, Hina ^a   Rohr, Joseph ^a,c   Heavican, Tayla B ^a   Wang, Chao ^a,c   Bouska, Alyssa ^a   Fu, Kai ^a   Chan, Wing C ^c,e   Vose, Julie M ^d,f  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c City of Hope Medical Center   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Gene expression profiling; Molecular classification; Molecular prognosis; Peripheral T cell lymphoma; Targeted therapy

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; STAT PROTEIN; ANTINEOPLASTIC AGENT;

ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; CANCER CELL; CANCER CLASSIFICATION; CANCER GENETICS; CANCER PROGNOSIS; CANCER SURVIVAL; FAILURE FREE SURVIVAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; GENE SIGNATURE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; MICROARRAY ANALYSIS; MOLECULAR DIAGNOSIS; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; TUMOR SUPPRESSOR GENE; CLINICAL TRIAL (TOPIC); DISEASE MANAGEMENT; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; LYMPHOMA, T-CELL; MOLECULARLY TARGETED THERAPY; MORTALITY; MUTATION; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; LYMPHOMA, T-CELL; MOLECULAR TARGETED THERAPY; MUTATION; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84940092892     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2015.08.003     Document Type: Article

References (109)

1. Rudiger T., Weisenburger D.D., Anderson J.R., et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002, 13(1):140-149.
2. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997, 89(11):3909-3918.
3. International peripheral T-cell and natural killer/t-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008, 26(25):4124-4130.
4. Swerdlow S.H., Campo E., Harris N.L., et al. WHO classification: pathology and genetics of tumors of haematopoietic and lymphoid tissues. WHO 2008, 4. IARC Press, Lyon, France.
5. Briski R., Feldman A.L., Bailey N.G., et al. The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. Blood Cancer J 2014, 4:e214.
6. Pearson P.L., Van der Luijt R.B. The genetic analysis of cancer. J Intern Med 1998, 243(6):413-417.
7. Saluz H.P., Iqbal J., Gino V.L., Andre R., Wu Z. Fundamentals of DNA-chip/array technology for comparative gene-expression analysis. Curr Sci 2002, 83:829-833.
8. Shendure J., Ji H. Next-generation DNA sequencing. Nat Biotechnol 2008, 26(10):1135-1145.
9. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403(6769):503-511.
10. Lenz G., Wright G., Dave S.S., et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359(22):2313-2323.
11. Monti S., Savage K.J., Kutok J.L., et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005, 105(5):1851-1861.
12. Rosenwald A., Wright G., Chan W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346(25):1937-1947.
13. Rosenwald A., Wright G., Wiestner A., et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3(2):185-197.
14. Dave S.S., Wright G., Tan B., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004, 351(21):2159-2169.
15. Dave S.S., Fu K., Wright G.W., et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006, 354(23):2431-2442.
16. Weisenburger D.D., Savage K.J., Harris N.L., et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011, 117(12):3402-3408.
17. de Leval L., Rickman D.S., Thielen C., et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007, 109(11):4952-4963.
18. Martinez-Delgado B. Peripheral T-cell lymphoma gene expression profiles. Hematol Oncol 2006, 24(3):113-119.
19. Piccaluga P.P., Agostinelli C., Califano A., et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res 2007, 67(22):10,703-10,710.
20. Piccaluga P.P., Agostinelli C., Califano A., et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 2007, 117(3):823-834.
21. Ballester B., Ramuz O., Gisselbrecht C., et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene 2006, 25(10):1560-1570.
22. Cuadros M., Dave S.S., Jaffe E.S., et al. Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J Clin Oncol 2007, 25(22):3321-3329.
23. Martinez-Delgado B., Cuadros M., Honrado E., et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia 2005, 19(12):2254-2263.
24. Tsuchiya T., Ohshima K., Karube K., et al. Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood 2004, 103(1):236-241.
25. Piccaluga P.P., Fuligni F., De Leo A., et al. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. J Clin Oncol 2013, 31(24):3019-3025.
26. Iqbal J., Weisenburger D.D., Greiner T.C., et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 2010, 115(5):1026-1036.
27. Iqbal J., Weisenburger D.D., Chowdhury A., et al. Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia 2011, 25(2):348-358.
28. Iqbal J., Wright G., Wang C., et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 2014, 123(19):2915-2923.
29. Wang T., Feldman A.L., Wada D.A., et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood 2014, 123(19):3007-3015.
30. Horwitz S.M., Porcu P., Flinn I., et al. 803 Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, Shows Activity in Patients with Relapsed/Refractory T-Cell Lymphoma. Paper presented at: 56th ASH Annual Meeting and Exposition December 6-9, 2014, [San Francisco, CA].
31. Rudiger T., Weisenburger D.D., Anderson J.R., et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. ESMO 2002, 13(1):140-149.
32. Vose J., Armitage J., Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008, 26(25):4124-4130.
33. Armitage J.O. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012, 87(5):511-519.
34. de Leval L., Gisselbrecht C., Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol 2010, 148(5):673-689.
35. Federico M., Rudiger T., Bellei M., et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol 2013, 31(2):240-246.
36. Mourad N., Mounier N., Briere J., et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2008, 111(9):4463-4470.
37. Xu B., Liu P. No survival improvement for patients with angioimmunoblastic T-cell lymphoma over the past two decades: a population-based study of 1207 cases. PLoS One 2014, 9(3).
38. Grogg K.L., Attygalle A.D., Macon W.R., Remstein E.D., Kurtin P.J., Dogan A. Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells?. Blood 2005, 106(4):1501-1502.
39. Cairns R.A., Iqbal J., Lemonnier F., et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 2012, 119(8):1901-1903.
40. Morris S.W., Kirstein M.N., Valentine M.B., et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1995, 267(5196):316-317.
41. Mason D.Y., Bastard C., Rimokh R., et al. CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35. Br J Haematol 1990, 74(2):161-168.
42. Morris S.W., Kirstein M.N., Valentine M.B., et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994, 263(5151):1281-1284.
43. Rimokh R., Magaud J.P., Berger F., et al. A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ('Ki-1 lymphoma'). Br J Haematol 1989, 71(1):31-36.
44. Piva R., Pellegrino E., Mattioli M., et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest 2006, 116(12):3171-3182.
45. Matsuyama H., Suzuki H.I., Nishimori H., et al. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood 2011, 118(26):6881-6892.
46. Agnelli L., Mereu E., Pellegrino E., et al. Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood 2012, 120(6):1274-1281.
47. Abate F., Todaro M., van der Krogt J.A., et al. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. Leukemia 2015, 29(6):1390-1401.
48. Parrilla Castellar E.R., Jaffe E.S., Said J.W., et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 2014, 124(9):1473-1480.
49. Crescenzo R., Abate F., Lasorsa E., et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 2015, 27(4):516-532.
50. Proietti F.A., Carneiro-Proietti A.B., Catalan-Soares B.C., Murphy E.L. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005, 24(39):6058-6068.
51. Franchini G., Nicot C., Johnson J.M. Seizing of T cells by human T-cell leukemia/lymphoma virus type 1. Adv Cancer Res 2003, 89:69-132.
52. Sasaki H., Nishikata I., Shiraga T., et al. Overexpression of a cell adhesion molecule, TSLC1, as a possible molecular marker for acute-type adult T-cell leukemia. Blood 2005, 105(3):1204-1213.
53. Pise-Masison C.A., Radonovich M., Dohoney K., et al. Gene expression profiling of ATL patients: compilation of disease related genes and evidence for TCF-4 involvement in BIRC5 gene expression and cell viability. Blood 2009, 113:4016-4026.
54. Huang Y., de Reynies A., de Leval L., et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal-type. Blood 2010, 115:1226-1237.
55. Kucuk C., Jiang B., Hu X., et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells. Nat Commun 2015, 6:6025.
56. Kucuk C., Iqbal J., Hu X., et al. PRDM1 is a tumor suppressor gene in natural killer cell malignancies. Proc Natl Acad Sci U S A 2011, 108(50):20,119-20,124.
57. Iqbal J., Kucuk C., Deleeuw R.J., et al. Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia 2009, 23(6):1139-1151.
58. Kucuk C., Hu X., Iqbal J., et al. HACE1 is a tumor suppressor gene candidate in natural killer cell neoplasms. Am J Pathol 2013, 182(1):49-55.
59. Travert M., Huang Y., de Leval L., et al. Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets. Blood 2012, 119(24):5795-5806.
60. Miyazaki K., Yamaguchi M., Imai H., et al. Gene expression profiling of peripheral T-cell lymphoma including gammadelta T-cell lymphoma. Blood 2009, 113(5):1071-1074.
61. Davis R.E., Brown K.D., Siebenlist U., Staudt L.M. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001, 194(12):1861-1874.
62. Bild A.H., Yao G., Chang J.T., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439(7074):353-357.
63. Rosenwald A., Wright G., Leroy K., et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003, 198(6):851-862.
64. Savage K.J., Monti S., Kutok J.L., et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003, 102(12):3871-3879.
65. Dunleavy K., Pittaluga S., Czuczman M.S., et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009, 113(24):6069-6076.
66. Zinzani P.L., Tani M., Musuraca G., et al. Phase II study of proteasome inhibitor bortezomib (Velcade®) in patients with relapsed/refractory T-cell lymphoma: preliminary results. Blood 2006, 108. [Abstract 2462].
67. Piva R., Ruggeri B., Williams M., et al. CEP-18,770: a novel orally-active proteasome inhibitor with a tumor-selective pharmacological profile competitive with bortezomib. Blood 2008, 111:2765-2775.
68. Querfeld C., Kuzel T., Guitart J. Preliminary results of a phase II study of Lenalidomide in patients with cutaneous T-cell lymphom. Blood 2005, 106:3351a.
69. Feldman A., Sun D., Law M. Syk tyrosine kinase is overexpressed in the majority of peripheral T and NK-cell lymphomas, and Re. Blood 2007, 110:690a.
70. Wilcox R.A., Sun D.X., Novak A., Dogan A., Ansell S.M., Feldman A.L. Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines. Leukemia 2010, 24(1):229-232.
71. Piccaluga P.P., Agostinelli C., Zinzani P.L., Baccarani M., Dalla Favera R., Pileri S.A. Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified. Lancet Oncol 2005, 6(6):440.
72. Laimer D., Dolznig H., Kollmann K., et al. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med 2012, 18(11):1699-1704.
73. Piccaluga P.P., Rossi M., Agostinelli C., et al. Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway. Leukemia 2014, 28:1687-1697.
74. Andrae J., Gallini R., Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008, 22(10):1276-1312.
75. Palomero T., Couronne L., Khiabanian H., et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 2014, 46(2):166-170.
76. Sakata-Yanagimoto M., Enami T., Yoshida K., et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 2014, 46(2):171-175.
77. Yoo H.Y., Sung M.K., Lee S.H., et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet 2014, 46(4):371-375.
78. Borroto A., Gil D., Delgado P., et al. Rho regulates T cell receptor ITAM-induced lymphocyte spreading in an integrin-independent manner. Eur J Immunol 2000, 30(12):3403-3410.
79. Rougerie P., Delon J. Rho GTPases: masters of T lymphocyte migration and activation. Immunol Lett 2012, 142(1-2):1-13.
80. Cleverley S.C., Costello P.S., Henning S.W., Cantrell D.A. Loss of Rho function in the thymus is accompanied by the development of thymic lymphoma. Oncogene 2000, 19(1):13-20.
81. Lemonnier F., Couronne L., Parrens M., et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 2012, 120(7):1466-1469.
82. Odejide O., Weigert O., Lane A.A., et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 2014, 123(9):1293-1296.
83. Asmar F., Punj V., Christensen J., et al. Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma. Haematologica 2013, 98(12):1912-1920.
84. Dawlaty M.M., Ganz K., Powell B.E., et al. Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell Stem Cell 2011, 9(2):166-175.
85. Xu W., Yang H., Liu Y., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19(1):17-30.
86. DiNardo C.D., Propert K.J., Loren A.W., et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 2013, 121(24):4917-4924.
87. Cheminant M., Bruneau J., Kosmider O., et al. Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma. Br J Haematol 2015, 168(6):913-916.
88. Nicolae A., Xi L., Pittaluga S., et al. Frequent STAT5B mutations in gammadelta hepatosplenic T-cell lymphomas. Leukemia 2014, 28(11):2244-2248.
89. Kiel M.J., Velusamy T., Rolland D., et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood 2014, 124(9):1460-1472.
90. Escalon M.P., Liu N.S., Yang Y., et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 2005, 103(10):2091-2098.
91. Greer J.P. Therapy of peripheral T/NK neoplasms. Hematol Am Soc Hematol Educ Program 2006, 331-337.
92. d' Amore F., Lauritzsen G., Jantunen E., et al. High-dose therapy (HDT) and autologous stem cell transplantation (ASCT) as first line treatment in peripheral T-cell lymphoma (PTCL). Ann Oncol 2005.
93. Rodriguez J., Munsell M., Yazji S., et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001, 19(17):3766-3770.
94. Rodriguez J., Conde E., Gutierrez A., et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007, 18(4):652-657.
95. Moskowitz A.J., Lunning M.A., Horwitz S.M. How I treat the peripheral T-cell lymphomas. Blood 2014, 123(17):2636-2644.
96. Zinzani P.L., Magagnoli M., Bendandi M., et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 1998, 9(12):1351-1353.
97. Piekarz R.L., Sackett D.L., Bates S.E. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer J 2007, 13(1):30-39.
98. O'Connor O., Hamlin P., Gerecitano J. PDX produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-cell lymphomas: results of the MSKCC phase I/II experience. Blood 2006, 108. [Abstract 400].
99. Redaelli S., Farina F., Stasia A., et al. High response rates to Crizotinib in advanced, chemoresistant ALK+ lymphoma patients. Blood 2013, 122(21):368.
100. Pro B., Advani R., Brice P., et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012, 30(18):2190-2196.
101. Horwitz S.M., Advani R.H., Bartlett N.L., et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 2014, 123(20):3095-3100.
102. O'Connor O.A., Pro B., Pinter-Brown L., et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011, 29(9):1182-1189.
103. Damaj G., Gressin R., Bouabdallah K., et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol 2013, 31(1):104-110.
104. Zinzani P.L., Venturini F., Stefoni V., et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 2010, 21(4):860-863.
105. Coiffier B., Pro B., Prince H.M., et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012, 30(6):631-636.
106. O'Connor O.A., Masszi T., Savage K.J., et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial [abstract]. J Clin Oncol 2013, 31:s850.
107. Dang N.H., Pro B., Hagemeister F.B., et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007, 136(3):439-447.
108. Toumishey E., Prasad A., Dueck G., et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer 2015, 121(5):716-723.
109. Enblad G., Hagberg H., Erlanson M., et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004, 103(8):2920-2924.